MY006 / Mabylon - LARVOL DELTA

MY006, a half-life extended trispecific IgG4 antibody for the prevention of allergic reactions to peanut (AAAAI 2026) - "Conclusions MY006 is being developed as a novel alternative to desensitization approaches, with the potential to offer peanut allergic patients long-lasting protection without allergen exposure, with an expected dosing of only few subcutaneous injections per year, owing to half-life extension, mechanism of action, and potency. MY006 is currently being evaluated in the clinics as a promising option for patients with severe peanut allergies."

Trispecific • Allergy • Food Hypersensitivity • Immunology

Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Mabylon AG | Not yet recruiting ➔ Recruiting

Enrollment open • Allergy • Food Hypersensitivity • Immunology

Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy (clinicaltrials.gov) - P1 | N=48 | Not yet recruiting | Sponsor: Mabylon AG

New P1 trial • Allergy • Food Hypersensitivity • Immunology